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Central to our understanding of acute myocardial infarction
(MI) is the tight relationship between myonecrosis and the
presence of elevated serum levels of certain enzymes known
to originate from within myocardial cells. Together with
presence of either chest discomfort or typical electrocardio-
graphic (ECG) changes, an elevation in cardiac enzymes
confirms the diagnosis of acute MI. Recently, even more
emphasis has been placed on the significance of the role of
serum enzymes. One publication revising criteria for acute
MI indicates that the isolated finding of enzyme elevation in
the setting of a percutaneous coronary intervention (PCI) is
sufficient for the diagnosis of acute MI (1). This change in
definition has major implications when gauging the risk/
benefit ratio of PCI, especially in comparison with alterna-
tive treatment options.
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The association between PCI and subsequent detection
of elevated levels of creatine kinase (CK), and in particular
its MB isoenzyme (CK-MB), is well documented (2).
Enzyme elevations are more common when balloon angio-
plasty is supplemented by additional procedures such as
atherectomy or stent implantation (3–5). The greater po-
tential for these adjunctive therapies to cause atheroembo-
lism with subsequent impairment of microvascular function
may explain this relationship (6). Approximately half of
instances of CK-MB elevation during PCI are associated
with chest pain syndromes, new ECG abnormalities, or
other events (e.g., abrupt closure, side branch occlusion, or
slow coronary flow), and there is agreement that such
occurrences can be considered as legitimate adverse events
(7).
More controversial has been the significance of elevations
of CK-MB after PCI in asymptomatic patients who appear
to have had an uncomplicated and successful procedure. Are
such patients experiencing true MIs in the classic sense, and
if so, are the consequences of these infarctions similar to
those that occur spontaneously? On one hand, certain data
indicate that asymptomatic CK-MB elevations are associ-
ated with an increased risk of late, adverse clinical events.
One report indicates that for PCI of aortocoronary saphe-
nous venous grafts, CK-MB elevations, even in an other-
wise uncomplicated procedure, are associated with late
mortality (8). A similar relationship between apparently
uncomplicated elevations of cardiac enzymes and outcome
may exist for native coronary arterial PCI when CK-MB
elevations are excessive, that is, 8 times normal (5). In
addition, one investigation using a contrast-enhanced mag-
netic resonance imaging technique suggests that even mild
elevations of CK-MB are associated image-detectable sites
of myocardial injury (9). On the other hand, a comparative
analysis indicates that the development of a Q-wave on the
ECG is associated with a far greater risk of late death than
even large isolated elevations in CK-MB (5). Also, milder
elevations in the 1 to 5 range may not be associated with
procedural, in-hospital, or late adverse events (4,7), al-
though not all agree on this finding (10,11). Importantly,
the prevalence of such events may actually become more
common because troponin T and troponin I appear to be
more sensitive markers than CK-MB (12,13).
The relationship between enzyme elevation and outcome
is of special importance given the well-documented ability
of glycoprotein IIb/IIIa antagonists to reduce the magnitude
and frequency of enzyme elevations among patients having
PCI (14–16). Routine administration of these agents,
however, incurs substantial financial expense and an in-
creased risk of procedure-related hemorrhage that in certain
instances can be serious or fatal (17).
The report by Iakovou et al. (18) in this issue of the
Journal adds another twist in our effort to understand the
significance of elevations in cardiac enzymes associated with
the use of intracoronary stents. Most coronary lesions
treated by balloon angioplasty also are stented. This practice
is based on the recognition that routine stent use is
associated with a lower likelihood of abrupt artery closure,
in-hospital MI, restenosis, and repeat revascularization by
either repeat PCI or coronary bypass surgery. Also well
acknowledged is the inverse relationship between stent
cross-sectional area at deployment and the likelihood of
developing in-stent restenosis. In other words, the larger the
stent area, the less is the chance for lesion recurrence within
the stent. This relationship is especially valid for bare metal
stents and to a lesser degree for sirolimus-eluting stents
(19). Iakovou et al. (18) confirmed this relationship in a
cohort of 989 consecutive patients who had intravascular
ultrasound as part of their stent implantation procedure.
Patients whose stent area exceeded that of the arterial lumen
area had the lowest incidence of target lesion revasculariza-
tion at one year of follow-up. Conversely, patients in the
group with the lowest stent area had the highest rate of
restenosis. A second finding was that a step-wise relation-
ship in the magnitude of peak periprocedural CK-MB levels
was observed according to the degree of stent expansion.
Thus, the proportion of patients experiencing mild or
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marked elevations in CK-MB was least among the group
with under-expanded stents and greatest among those with
optimal stent expansion. Patients with intermediate stent
expansion had enzyme findings that fell between the two
other groups.
At first glance, each of these findings appears straight-
forward and consistent with our background knowledge of
PCI and enzyme response. Optimal stent outcome, in terms
of avoiding restenosis, means aggressive initial stent expan-
sion achieved by high-pressure balloon inflations. This
strategy, however, carries with it the risk of incremental
distal atheroembolization, myonecrosis, and enzyme eleva-
tion. Continuing this reasoning, one would expect to
observe a greater incidence of adverse events during the
course of follow-up among the optimal stent group. This,
however, was not the case. Paradoxically, the incidences of
in-hospital death, Q-wave MI, and emergency bypass sur-
gery were similar and low among the three groups. For
example, although more than half of the patients in the
optimal stent deployment group had elevations of CK-MB,
only 1% had Q-wave MI, and only 0.2% died during the
hospitalization. Even at one year of follow-up, there were
no differences in the cumulative rates of Q-wave MI or
death. In fact, the lowest mortality rate was among the
optimal stent (highest CK-MB) group.
Before attempting to interpret the findings of this pro-
vocative study, we must address certain questions. First, are
the observations really correct? Is there indeed no added risk
of adverse late clinical events from aggressive stent expan-
sion and associated increased incidence of myonecrosis? If
the investigation were repeated with different patients at
different sites, would there still be no difference in one-year
mortality? These questions cannot be answered directly.
However, it is possible that the groups in this report were
too small to detect true differences or that there was an
imbalance of selected characteristics at baseline, for exam-
ple, impaired renal function, that could influence late
mortality.
Second, is it possible that optimal stent expansion confers
benefits beyond in-stent restenosis that offset the deleterious
influence of myonecrosis? For instance, more robust stent
deployment may lower the chance for stent thrombosis, a
complication that can result in MI and death.
Third, was the length of follow-up in this report sufficient
time to detect the effect of subtle differences in myonecrosis
on mortality? Perhaps the rates of adverse events at five years
will differ from those at one year.
Fourth, in the era of drug-eluting stents, will the criteria
for achieving “optimal” stent deployment change? Will it be
necessary for stent cross-sectional area to match or exceed
lumen cross-sectional area? Although data to answer this
question are limited at present, at least one investigation
suggests that smaller stent cross-sectional areas are accept-
able if sirolimus-eluting rather than bare-metal stents are
used (20). If true, more modest deployment inflation pres-
sures with less lesion barotrauma may diminish the fre-
quency and magnitude of cardiac enzyme elevations.
In the final analysis, it appears clear that PCI-related
elevations in cardiac enzymes are frequent and are statisti-
cally associated with less favorable late outcomes. Even if
unassociated with other peri-procedural adverse clinical
events, isolated enzyme elevations carry some risk. For
patients receiving stents, however, these potential deleteri-
ous influences appear to be of insufficient magnitude to
offset the beneficial effects of optimal stent deployment
when measured by important, late clinical events.
In addition, the findings of this investigation have impli-
cations that extend beyond its immediate objective. Those
who classify isolated enzyme elevations during PCI as being
equivalent to spontaneous ST-elevation infarction due to
proximal coronary occlusion should take note. Although
both events may reflect myonecrosis, they differ substantially
in their consequences and should be considered as distinctly
different events, particularly when making formal compari-
sons of therapeutic options.
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